The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Abstract Advances in antibody-drug conjugate (ADC) technology and identification of new antigen targets are repositioning ADCs as a promising therapeutic platform for metastatic castration-resistant prostate cancer (mCRPC). This review summarizes recent progress in ADC payload and linker chemistry,...
Tallennettuna:
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Portfolio
2025-11-01
|
| Sarja: | npj Precision Oncology |
| Linkit: | https://doi.org/10.1038/s41698-025-01131-0 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|